JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by McIlroy, D. R. Articles by Silvers, A. J. Search for Related Content PubMed PubMed Citation Articles by McIlroy, D. R. Articles by Silvers, A. J. Related Collections Cardiovascular Blood Heart

---

CARDIOVASCULAR ANESTHESIA

Recombinant Factor VIIa for Life-Threatening Bleeding in High-Risk Cardiac Surgery Despite Full-Dose Aprotinin

Department of Anaesthesia and Pain Management, Alfred Hospital, Melbourne, Australia

Address correspondence and reprint requests to Dr. David R. McIlroy, Department of Anaestheisa and Pain Management, Alfred Hospital, Commercial Rd., Melbourne 3004, Victoria, Australia. Address e-mail to d.mcilroy{at}alfred.org.au

We report the case of an orthotopic heart transplant in a patient with multiple previous cardiac surgeries. The case was prolonged and complicated by severe coagulopathy and bleeding despite the use of full-dose aprotinin throughout. Bleeding was not controlled after 30 U of platelets, 20 U of fresh frozen plasma, and 10 U of cryoprecipitate. However, after the administration of recombinant factor VIIa 90 µg/kg, the rate of bleeding slowed dramatically and no further factor replacement was required. There was no evidence of unwanted clot formation within the newly transplanted heart or around the intraaortic balloon pump that remained in situ for 72 h postoperatively. With the combined risks of coagulopathy and bleeding as well as acute right ventricular failure with increases in pulmonary vascular resistance, the re-do sternotomy for heart transplant seems to be an ideal situation in which to consider the use of recombinant factor VIIa.

IMPLICATIONS: Despite full-dose prophylactic aprotinin and aggressive treatment of coagulopathy in a high-risk cardiac surgical case, life-threatening microvascular bleeding was controlled only after the administration of recombinant factor VIIa. There was no evidence of prothrombotic complications.

This article has been cited by other articles:

				O. Warren, K. Mandal, V. Hadjianastassiou, L. Knowlton, S. Panesar, K. John, A. Darzi, and T. Athanasiou Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review Ann. Thorac. Surg., February 1, 2007; 83(2): 707 - 714. [Abstract] [Full Text] [PDF]

				S. Romagnoli, S. Bevilacqua, S. Gelsomino, S. Pradella, L. Ghilli, C. Rostagno, G. F. Gensini, and C. Sorbara Small-Dose Recombinant Activated Factor VII (NovoSeven(R)) in Cardiac Surgery. Anesth. Analg., May 1, 2006; 102(5): 1320 - 1326. [Abstract] [Full Text] [PDF]

				M. Hyllner, E. Houltz, and A. Jeppsson Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery Eur. J. Cardiothorac. Surg., August 1, 2005; 28(2): 254 - 258. [Abstract] [Full Text] [PDF]

				P. Raivio, R. Suojaranta-Ylinen, and A. H. Kuitunen Recombinant Factor VIIa in the Treatment of Postoperative Hemorrhage After Cardiac Surgery Ann. Thorac. Surg., July 1, 2005; 80(1): 66 - 71. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999